{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:26:32Z","timestamp":1788143192220,"version":"build-2803163510"},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"6","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Foundation for Growth Science","award":["32"],"award-info":[{"award-number":["32"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2020-0734_abs_001_w2aab3b7c47b1b6b1aab1c16b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>X-linked hypophosphatemic rickets (XLH) is a congenital fibroblast growth factor (FGF)23-related metabolic bone disease that is treated with active vitamin D and phosphate as conventional therapies. Complications of these therapies include nephrocalcinosis (NC) caused by excessive urine calcium and phosphate concentrations. Recently, an anti-FGF23 antibody, burosumab, was developed and reported to be effective in poorly-controlled or severe XLH patients. This study aimed to reveal the impact of switching treatments in relatively well-controlled XLH children with the Rickets Severity Scale less than 2.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0734_abs_002_w2aab3b7c47b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The effects of the two treatments in eight relatively well-controlled XLH children with a mean age of 10.4 \u00b1 1.9 years were compared retrospectively for the same treatment duration (31 \u00b1 11 months) before and after the baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0734_abs_003_w2aab3b7c47b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Actual doses of alfacalcidol and phosphate as conventional therapy were 150.9 \u00b1 43.9 ng\/kg and 27.5 \u00b1 6.3 mg\/kg per day, respectively. Renal echography revealed spotty NC in 8\/8 patients, but no aggravation of NC was detected by switching treatments. Switching treatments increased TmP\/GFR (p=0.002) and %TRP (p&lt;0.001), and improved the high urine calcium\/creatinine ratio to the normal range (p&lt;0.001) although both treatments controlled disease markers equally. Additionally, low intact parathyroid hormone during conventional therapy was increased within the normal range by switching treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2020-0734_abs_004_w2aab3b7c47b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results suggest that a high dose of alfacalcidol was needed to control the disease, but it caused hypercalciuria and NC. We concluded that switching treatments in relatively well-controlled XLH children improved renal phosphate reabsorption and decreased urine calcium extraction, and may have the potential to prevent NC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2020-0734","type":"journal-article","created":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T05:10:54Z","timestamp":1618031454000},"page":"791-798","source":"Crossref","is-referenced-by-count":17,"title":["Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets"],"prefix":"10.1515","volume":"34","author":[{"given":"Daisuke","family":"Harada","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Ueyama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Oriyama","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Ishiura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Seino","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Osaka Hospital , Japan Community Healthcare Organization (JCHO) , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"2023040101193736105_j_jpem-2020-0734_ref_001_w2aab3b7c47b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Albright, F, Butler, AM, Bloomberg, E. Rickets resistant to vitamin D therapy. Arch J Dis Child 1937;54:529\u201347. https:\/\/doi.org\/10.1001\/archpedi.1937.01980030073005.","DOI":"10.1001\/archpedi.1937.01980030073005"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_002_w2aab3b7c47b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Lobaugh, B, Drezner, MK. Abnormal regulation of renal 25-dihydroxyvitamin D-1\u03b1-hydroxylase activity in the X-linked hypophosphatemic mouse. J Clin Invest 1983;71:400\u20133. https:\/\/doi.org\/10.1172\/jci110783.","DOI":"10.1172\/JCI110783"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_003_w2aab3b7c47b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Endo, I, Fukumoto, S, Ozono, K, Namba, N, Inoue, D, Okazaki, R, et al.. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 2015;62:811\u20136. https:\/\/doi.org\/10.1507\/endocrj.ej15-0275.","DOI":"10.1507\/endocrj.EJ15-0275"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_004_w2aab3b7c47b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Francis, F, Hennig, S, Korn, B, Reinhardt, R, de Jong, P, Poustka, A, et al.. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995;11:130\u20136. https:\/\/doi.org\/10.1038\/ng1095-130.","DOI":"10.1038\/ng1095-130"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_005_w2aab3b7c47b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Gattineni, J, Bates, C, Twombley, K, Dwarakanath, V, Robinson, ML, Goetz, R, et al.. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in\u00a0vivo predominantly via FGF receptor 1. Am J Physiol Ren Physiol 2009;297:F282\u201391. https:\/\/doi.org\/10.1152\/ajprenal.90742.2008.","DOI":"10.1152\/ajprenal.90742.2008"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_006_w2aab3b7c47b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Shimada, T, Hasegawa, H, Yamazaki, Y, Muto, T, Hino, R, Takeuchi, Y, et al.. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429\u201335.","DOI":"10.1359\/JBMR.0301264"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_007_w2aab3b7c47b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Costa, T, Marie, PJ, Scriver, CR, Cole, DE, Reade, TM, Nogrady, B, et al.. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab 1981;52:463\u201372. https:\/\/doi.org\/10.1210\/jcem-52-3-463.","DOI":"10.1210\/jcem-52-3-463"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_008_w2aab3b7c47b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Skrinar, A, Dvorak-Ewell, M, Evins, A, Macica, C, Linglart, A, Imel, EA, et al.. The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc 2019;3:1321\u201334. https:\/\/doi.org\/10.1210\/js.2018-00365.","DOI":"10.1210\/js.2018-00365"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_009_w2aab3b7c47b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Chesher, D, Oddy, M, Darbar, U, Sayal, P, Casey, A, Ryan, A, et al.. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 2018;41:865\u201376. https:\/\/doi.org\/10.1007\/s10545-018-0147-6.","DOI":"10.1007\/s10545-018-0147-6"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_010_w2aab3b7c47b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Verge, CF, Lam, A, Simpson, JM, Cowell, CT, Howard, NJ, Silink, M, et al.. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991;325:1843\u20138. https:\/\/doi.org\/10.1056\/nejm199112263252604.","DOI":"10.1056\/NEJM199112263252604"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_011_w2aab3b7c47b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Shavit, L, Ferraro, PM, Johri, N, Robertson, W, Walsh, SB, Moochhala, S, et al.. Effect of being overweight on urinary metabolic risk factors for kidney stone formation. Nephrol Dial Transplant 2015;30:607\u201313. https:\/\/doi.org\/10.1093\/ndt\/gfu350.","DOI":"10.1093\/ndt\/gfu350"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_012_w2aab3b7c47b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Pozdzik, A, Maalouf, N, Letavernier, E, Brocheriou, I, Body, JJ, Vervaet, B, et al.. Meeting report of the \u201csymposium on kidney stones and mineral metabolism: calcium kidney stones in 2017\u201d. J Nephrol 2019;32:681\u201398. https:\/\/doi.org\/10.1007\/s40620-019-00587-1.","DOI":"10.1007\/s40620-019-00587-1"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_013_w2aab3b7c47b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Habbig, S, Beck, BB, Hoppe, B. Nephrocalcinosis and urolithiasis in children. Kidney Int 2011;80:1278\u201391. https:\/\/doi.org\/10.1038\/ki.2011.336.","DOI":"10.1038\/ki.2011.336"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_014_w2aab3b7c47b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Hoppe, B, Kemper, MJ. Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol 2010;25:403\u201313. https:\/\/doi.org\/10.1007\/s00467-008-1073-x.","DOI":"10.1007\/s00467-008-1073-x"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_015_w2aab3b7c47b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Carpenter, TO, Imel, EA, Holm, IA, de Beur, SMJ, Insogna, KL. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381\u20138. https:\/\/doi.org\/10.1002\/jbmr.340.","DOI":"10.1002\/jbmr.340"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_016_w2aab3b7c47b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Makitie, O, Doria, A, Kooh, SW, Cole, WG, Daneman, A, Sochett, E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003;88:3591\u20137. https:\/\/doi.org\/10.1210\/jc.2003-030036.","DOI":"10.1210\/jc.2003-030036"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_017_w2aab3b7c47b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Carpenter, TO, Imel, EA, Ruppe, MD, Weber, TJ, Klausner, MA, Wooddell, MM, et al.. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 2014;124:1587\u201397. https:\/\/doi.org\/10.1172\/jci72829.","DOI":"10.1172\/JCI72829"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_018_w2aab3b7c47b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Imel, EA, Zhang, X, Ruppe, MD, Weber, T, Klausner, MA, Ito, T, et al.. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 2015;100:2565\u201373. https:\/\/doi.org\/10.1210\/jc.2015-1551.","DOI":"10.1210\/jc.2015-1551"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_019_w2aab3b7c47b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Cheong, HI, Yoo, HW, Adachi, M, Tanaka, H, Fujiwara, I, Hasegawa, Y, et al.. First-in-Asian phase I study of the anti-fibroblast growth factor 23 monoclonal antibody, burosumab: safety and pharmacodynamics in adults with X-linked hypophosphatemia. JBMR Plus 2019;3:e10074. https:\/\/doi.org\/10.1002\/jbm4.10074.","DOI":"10.1002\/jbm4.10074"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_020_w2aab3b7c47b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Imel, EA, Glorieux, FH, Whyte, MP, Munns, CF, Ward, LM, Nilsson, O, et al.. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 2019;393:2416\u201327. https:\/\/doi.org\/10.1016\/s0140-6736(19)30654-3.","DOI":"10.1016\/S0140-6736(19)30654-3"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_021_w2aab3b7c47b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Thacher, TD, Pettifor, JM, Tebben, PJ, Creo, AL, Skrinar, A, Mao, M, et al.. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: utility of the radiographic rickets severity score. Bone 2019;122:76\u201381. https:\/\/doi.org\/10.1016\/j.bone.2019.02.010.","DOI":"10.1016\/j.bone.2019.02.010"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_022_w2aab3b7c47b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Boyce, AM, Shawker, TH, Hill, SC, Choyke, PL, Hill, MC, James, R, et al.. Ultrasound is superior to computed tomography for assessment of medullary nephrocalcinosis in hypoparathyroidism. J Clin Endocrinol Metab 2013;98:989\u201394. https:\/\/doi.org\/10.1210\/jc.2012-2747.","DOI":"10.1210\/jc.2012-2747"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_023_w2aab3b7c47b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Evan, AP, Lingeman, J, Coe, F, Shao, Y, Miller, N, Matlaga, B, et al.. Renal histopathology of stone-forming patients with distal renal tubular acidosis. Kidney Int 2007;71:795\u2013801. https:\/\/doi.org\/10.1038\/sj.ki.5002113.","DOI":"10.1038\/sj.ki.5002113"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_024_w2aab3b7c47b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Ichihara, K, Yomamoto, Y, Hotta, T, Hosogaya, S, Miyachi, H, Itoh, Y, et al.. Collaborative derivation of reference intervals for major clinical laboratory tests in Japan. Ann Clin Biochem 2016;53:347\u201356. https:\/\/doi.org\/10.1177\/0004563215608875.","DOI":"10.1177\/0004563215608875"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_025_w2aab3b7c47b1b6b1ab2b2c25Aa","unstructured":"Committee on Enzyme and Reagent & Japan Society of Clinical Chemistry. About modified methods of measuring ALP and LD: for medical staff (ver.1.0) [in Japanese]. Available from: http:\/\/jscc-jp.gr.jp\/file\/2019\/alpld2.pdf [Accessed 08 Oct 2019]."},{"key":"2023040101193736105_j_jpem-2020-0734_ref_026_w2aab3b7c47b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Haffner, D, Emma, F, Eastwood, DM, Duplan, MB, Bacchetta, J, Schnabel, D, et al.. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019;15:435\u201355. https:\/\/doi.org\/10.1038\/s41581-019-0152-5.","DOI":"10.1038\/s41581-019-0152-5"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_027_w2aab3b7c47b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Miyamoto, J, Koto, S, Hasegawa, Y. Final height of Japanese patients with X-linked hypophosphatemic rickets: effect of vitamin D and phosphate therapy. Endocr J 2000;7:163\u20137. https:\/\/doi.org\/10.1507\/endocrj.47.163.","DOI":"10.1507\/endocrj.47.163"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_028_w2aab3b7c47b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Marwaha, RK, Garg, MK, Dang, N, Mithal, A, Narang, A, Chadha, A, et al.. Reference range of random urinary calcium creatinine ratio in North Indian children and adolescents. Ann Pediatr Endocrinol Metab 2019;24:34\u201340. https:\/\/doi.org\/10.6065\/apem.2019.24.1.34.","DOI":"10.6065\/apem.2019.24.1.34"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_029_w2aab3b7c47b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Qui\u00f1ones-V\u00e1zquez, S, Liriano-Ricabal, MDR, Santana-Porb\u00e9n, S, Salabarr\u00eda-Gonz\u00e1lez, JR. Calcium-creatinine ratio in a morning urine sample for the estimation of hypercalciuria associated with non-glomerular hematuria observed in children and adolescents. Bol Med Hosp Infant Mex 2018;75:41\u20138.","DOI":"10.24875\/BMHIME.M18000023"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_030_w2aab3b7c47b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Coe, FL, Evan, AP, Worcester, EM, Lingeman, JE. Three pathways for human kidney stone formation. Urol Res 2010;38:147\u201360. https:\/\/doi.org\/10.1007\/s00240-010-0271-8.","DOI":"10.1007\/s00240-010-0271-8"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_031_w2aab3b7c47b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Shavit, L, Jaeger, P, Unwin, RJ. What is nephrocalcinosis? Kidney Int 2015;88:35\u201343. https:\/\/doi.org\/10.1038\/ki.2015.76.","DOI":"10.1038\/ki.2015.76"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_032_w2aab3b7c47b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Taylor, A, Sherman, NH, Norman, ME. Nephrocalcinosis in X-linked hypophosphatemia: effect of treatment versus disease. Pediatr Nephrol 1995;9:173\u20135. https:\/\/doi.org\/10.1007\/bf00860736.","DOI":"10.1007\/BF00860736"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_033_w2aab3b7c47b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Hu, H, Zhang, J, Lu, Y, Zhang, Z, Qin, B, Gao, H, et al.. Association between circulating vitamin D level and urolithiasis: a systematic review and meta-analysis. Nutrients 2017;9:301. https:\/\/doi.org\/10.3390\/nu9030301.","DOI":"10.3390\/nu9030301"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_034_w2aab3b7c47b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Curhan, GC, Willett, WC, Speizer, FE, Spiegelman, D, Stampfer, MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126:497\u2013504. https:\/\/doi.org\/10.7326\/0003-4819-126-7-199704010-00001.","DOI":"10.7326\/0003-4819-126-7-199704010-00001"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_035_w2aab3b7c47b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Wiener, SV, Ho, SP, Stoller, ML. Beginnings of nephrolithiasis: insights into the past, present and future of Randall\u2019s plaque formation research. Curr Opin Nephrol Hypertens 2018;27:236\u201342. https:\/\/doi.org\/10.1097\/mnh.0000000000000414.","DOI":"10.1097\/MNH.0000000000000414"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_036_w2aab3b7c47b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Insogna, KL, Briot, K, Imel, EA, Kamenick\u00fd, P, Ruppe, MD, Portale, AA, et al.. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 2018;33:1383\u201393. https:\/\/doi.org\/10.1002\/jbmr.3475.","DOI":"10.1002\/jbmr.3475"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_037_w2aab3b7c47b1b6b1ab2b2c37Aa","doi-asserted-by":"crossref","unstructured":"Portale, AA, Carpenter, TO, Brandi, ML, Briot, K, Cheong, HI, Cohen-Solal, M, et al.. Continued beneficial effects of burosumab in adults with X-linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int 2019;105:271\u201384. https:\/\/doi.org\/10.1007\/s00223-019-00568-3.","DOI":"10.1007\/s00223-019-00568-3"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_038_w2aab3b7c47b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Mart\u00edn Ramos, S, Gil-Calvo, M, Rold\u00e1n, V, Castellano Mart\u00ednez, A, Santos, F. Positive response to one-year treatment with burosumab in pediatric patients with X-linked hypophosphatemia. Front Pediatr 2020;8:48. https:\/\/doi.org\/10.3389\/fped.2020.00048.","DOI":"10.3389\/fped.2020.00048"},{"key":"2023040101193736105_j_jpem-2020-0734_ref_039_w2aab3b7c47b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Amir, E, Simmons, CE, Freedman, OC, Dranitsaris, G, Cole, DEC, Vieth, R, et al.. A phase 2 trial exploring the effects of high-dose (10,000\u00a0IU\/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer 2010;116:284\u201391. https:\/\/doi.org\/10.1002\/cncr.24749.","DOI":"10.1002\/cncr.24749"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0734\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0734\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T19:23:27Z","timestamp":1680377007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2020-0734\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,6]]},"published-print":{"date-parts":[[2021,6,25]]}},"alternative-id":["10.1515\/jpem-2020-0734"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2020-0734","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,12]]}}}